Evidence method
Level · gp.fundamentals.debt_to_revenue
317.32% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Mar 31, 2022
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-22-000016General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
8.37% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-80.27% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
20.10% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
36.82% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
89.00% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-68.80% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
79.67% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
13.74% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 9.05%
- Current
- 8.37%
- Delta
- -0.67%
- Previous
- -76.00%
- Current
- -80.27%
- Delta
- -4.27%
- Previous
- 71.31%
- Current
- 20.10%
- Delta
- -51.20%
- Previous
- 10.23%
- Current
- 36.82%
- Delta
- 26.59%
- Previous
- 86.38%
- Current
- 89.00%
- Delta
- 2.62%
- Previous
- -83.93%
- Current
- -68.80%
- Delta
- 15.13%
- Previous
- 93.83%
- Current
- 79.67%
- Delta
- -14.16%
- Previous
- 19.63%
- Current
- 13.74%
- Delta
- -5.89%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.